Nav: Home

Is your lung cancer really ROS1-negative?

August 08, 2018

Drugs like crizotinib are used to treat patients with ROS1-positive lung cancer. But which patients are ROS1-positive? A University of Colorado Cancer Center study published in the Journal of Thoracic Oncology shows that common laboratory tests used to determine ROS1 status all have inherent limitations that can lead to false-negative results. Some samples that were determined to be ROS1-negative by one test were shown to be ROS1-positive by another, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks.

A commonly used test, based on a technique known as fluorescence in situ hybridization (FISH), provided a false negative for 2 of 20 samples known to be ROS1-positive; a test that sequences and analyzes ROS1 DNA was negative in 4 of 18 positive samples; and a test that looks for ROS1 fusion RNA was negative in 3 of 19 positive samples.

"The main point is just to be aware of the deficiencies in these assays and not to always trust a negative result from a single test. If you're suspicious that a patient could be ROS1-positive - maybe they're a never-smoker without other known drivers such as EGFR, ALK, KRAS, BRAF - then it may be useful to try another kind of test," says Kurtis Davies, PhD, Lead Assay Development Scientist at the Colorado Molecular Correlates Laboratory (CMOCO).

Davies, the study's first author, worked closely with colleagues including senior authors Robert C. Doebele, MD, PhD, director of the CU Cancer Center Thoracic Oncology Research Initiative, and Dara Aisner, MD, PhD, CMOCO Director in the CU Department of Pathology, which routinely employs multiple modes of testing cancer specimens.

"The University of Colorado has been a big player in the clinical research of ROS1 lung cancer, and so we have a lot more ROS1-positive samples than almost anywhere else. This allowed us to go back to our large bank of samples to test them in these three ways," Davies says.

The study found that each test has inherent deficiencies. ROS1-positive cancers are caused by the gene ROS1 fusing with one of a number of partner genes. One of these possible partners sits very near to ROS1 on chromosome 6. When ROS1 fuses with this nearby partner, there may not be enough DNA deleted to identify the fusion using FISH.

"It can leave enough of the FISH probe binding sites that the sample appears normal even though a ROS1 fusion is present," Davies says.

The deficiency in the DNA-based test was due to the inherent inability to properly sequence large areas of the ROS1 gene.

"You have large swaths of un-sequenced DNA and if the ROS1 change is in one of those areas, it's possible to miss it," Davies says.

"Some regions of DNA can be very challenging to sequence due to highly repetitive sequences, so simply trying to sequence those regions doesn't necessarily fix the deficit," Aisner says.

Unlike the other two tests, the assay based on RNA doesn't attempt to take a snapshot of altered ROS1 DNA. Instead, it looks at what is manufactured from the DNA. This means that an RNA-based assay has the potential to more directly test for the results of ROS1 gene fusion that can drive cancer. That is, as long as you have good enough RNA.

"The deficiency in assays based on RNA is that they depend on RNA quality, which can be bad in clinical samples," Davies says.

On the plus side, pathologists looking at the assay data can tell if RNA is of high enough quality to believe test results. ("We know when RNA quality is low," Davies says.) In these cases, the FISH or DNA test could be used. And the false-negatives attributed to the RNA assay in this study were all due to low RNA quality.

"If you take out the negatives due to RNA quality (which we don't really regard as negative), there were no false negatives with this kind of test," Davies says.

Again, according to Davies, the takeaway is to realize there is no perfect test and sometimes secondary analysis with a different test is necessary to confirm results. The strategy is more than theory.

"We've run FISH concurrently with the RNA test for the past 18 months," Davies says. "This helps us to provide every reassurance that we are not missing patients who can benefit from ROS1 directed therapy."

The strategy of testing by two methods has paid off.

"One of the patients included in this study was initially determined to be ROS1-negative via FISH, but was subsequently shown to be ROS1-positive via RNA," Aisner says. "This patient went on to receive ROS1 targeted therapy and demonstrated an impressive response."
-end-


University of Colorado Anschutz Medical Campus

Related Lung Cancer Articles:

AI helps to fight against lung cancer
Lung cancer has been the leading cause of cancer-related deaths in 2015 in United States.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
Antioxidants and lung cancer risk
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
Lung cancer may go undetected in kidney cancer patients
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
High levels of estrogen in lung tissue related to lung cancer in postmenopausal women
Researchers from Kumamoto University, Japan have found that postmenopausal women with multicentric adenocarcinoma of the lung have a higher concentration of estrogen in non-cancerous areas of the peripheral lung than similar women diagnosed with single tumor lung cancer.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Pericardial window operation less efficient in cases of lung cancer than any other cancer
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer.

Related Lung Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".